Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
1986 1
1993 3
1995 2
1996 4
1997 4
1998 3
1999 3
2000 3
2001 5
2002 4
2003 6
2004 5
2005 3
2006 6
2007 3
2008 3
2009 5
2010 7
2011 7
2012 9
2013 5
2014 11
2015 10
2016 7
2017 6
2018 9
2019 11
2020 11
2021 10
2022 15
2023 20
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

179 results

Results by year

Filters applied: . Clear all
Page 1
Review article: New developments in biomarkers and clinical drug development in alpha-1 antitrypsin deficiency-related liver disease.
Loomba R, Clark G, Teckman J, Ajmera V, Behling C, Brantly M, Brenner D, D'Armiento J, Fried MW, Iyer JS, Mandorfer M, Rockey DC, Tincopa M, Vuppalanchi R, Younossi Z, Krag A, Turner AM, Strnad P. Loomba R, et al. Among authors: behling c. Aliment Pharmacol Ther. 2024 May;59(10):1183-1195. doi: 10.1111/apt.17967. Epub 2024 Mar 22. Aliment Pharmacol Ther. 2024. PMID: 38516814 Review.
Investigating the Relationship Between Rare Genetic Variants and Fibrosis in Pediatric Nonalcoholic Fatty Liver Disease.
Wattacheril J, Kleinstein SE, Shea PR, Wilson LA, Subramanian GM, Myers RP, Lefkowitch J, Behling C, Xanthakos SA, Goldstein DB; NASH Clinical Research Network. Wattacheril J, et al. Among authors: behling c. medRxiv [Preprint]. 2024 Mar 4:2024.03.02.24303632. doi: 10.1101/2024.03.02.24303632. medRxiv. 2024. PMID: 38496563 Free PMC article. Preprint.
Nutrition assessment and MASH severity in children using the Healthy Eating Index.
Jain AK, Buchannan P, Yates KP, Belt P, Schwimmer JB, Rosenthal P, Murray KF, Molleston JP, Scheimann A, Xanthakos SA, Behling CA, Hertel P, Nilson J, Neuschwander-Tetri BA, Tonascia J, Vos MB; Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN). Jain AK, et al. Among authors: behling ca. Hepatol Commun. 2023 Dec 7;7(12):e0320. doi: 10.1097/HC9.0000000000000320. eCollection 2023 Dec 1. Hepatol Commun. 2023. PMID: 38055641 Free PMC article.
Artificial intelligence-assisted digital pathology for non-alcoholic steatohepatitis: current status and future directions.
Ratziu V, Hompesch M, Petitjean M, Serdjebi C, Iyer JS, Parwani AV, Tai D, Bugianesi E, Cusi K, Friedman SL, Lawitz E, Romero-Gómez M, Schuppan D, Loomba R, Paradis V, Behling C, Sanyal AJ. Ratziu V, et al. Among authors: behling c. J Hepatol. 2024 Feb;80(2):335-351. doi: 10.1016/j.jhep.2023.10.015. Epub 2023 Oct 24. J Hepatol. 2024. PMID: 37879461 Review.
Liver biopsy for assessment of suspected drug-induced liver injury in metabolic dysfunction-associated steatohepatitis clinical trials: Expert consensus from the Liver Forum.
Palmer M, Kleiner DE, Goodman Z, Brunt E, Avigan MI, Regev A, Hayashi PH, Lewis JH, Mehta R, Harrison SA, Siciliano M, McWherter CA, Vuppalanchi R, Behling C, Miller V, Chalasani N, Sanyal AJ. Palmer M, et al. Among authors: behling c. Aliment Pharmacol Ther. 2024 Jan;59(2):201-216. doi: 10.1111/apt.17762. Epub 2023 Oct 25. Aliment Pharmacol Ther. 2024. PMID: 37877759
Development of Fibro-PeN, a clinical prediction model for moderate-to-severe fibrosis in children with nonalcoholic fatty liver disease.
Wang A, Blackford AL, Behling C, Wilson LA, Newton KP, Xanthakos SA, Fishbein MH, Vos MB, Mouzaki M, Molleston JP, Jain AK, Hertel P, Harlow Adams K, Schwimmer JB; NASH CRN. Wang A, et al. Among authors: behling c. Hepatology. 2023 Oct 23:10.1097/HEP.0000000000000644. doi: 10.1097/HEP.0000000000000644. Online ahead of print. Hepatology. 2023. PMID: 37870272
Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial.
Harrison SA, Frias JP, Neff G, Abrams GA, Lucas KJ, Sanchez W, Gogia S, Sheikh MY, Behling C, Bedossa P, Shao L, Chan D, Fong E, de Temple B, Shringarpure R, Tillman EJ, Rolph T, Cheng A, Yale K; HARMONY Study Group. Harrison SA, et al. Among authors: behling c. Lancet Gastroenterol Hepatol. 2023 Dec;8(12):1080-1093. doi: 10.1016/S2468-1253(23)00272-8. Epub 2023 Oct 3. Lancet Gastroenterol Hepatol. 2023. PMID: 37802088 Clinical Trial.
179 results